Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
The solvency profile indicates a consistent long-term trend of deleveraging and a reduction in financial risk between April 2022 and March 2026. There is a clear strategic shift toward a more equity-heavy capital structure, characterized by a steady decline in debt-related ratios across the observed period.
- Debt-to-Equity, Debt-to-Capital, and Debt-to-Assets Ratios
- These three metrics exhibit a synchronized downward trajectory. The debt-to-equity ratio decreased from 0.47 in April 2022 to a low of 0.32 in December 2024, eventually stabilizing at 0.35 by March 2026. Similarly, the debt-to-capital ratio declined from 0.32 to 0.26, and the debt-to-assets ratio moved from 0.26 to 0.22. This trend suggests a deliberate reduction in total debt obligations relative to the company's asset base and shareholder equity.
- Financial Leverage
- Financial leverage followed a similar pattern of reduction, falling from 1.80 in April 2022 to 1.58 in March 2026. The most significant contraction occurred between September 2023 and March 2024, where the ratio dropped from 1.67 to 1.56. This decrease reflects a lower reliance on borrowed funds to finance assets, which generally enhances the organization's long-term financial stability.
- Interest Coverage Ratio
- In contrast to the leverage ratios, the interest coverage ratio experienced a significant downward trend. After reaching a peak of 41.32 in September 2022, the ratio declined steadily to a minimum of 15.01 in June 2025, before recovering slightly to 17.95 by March 2026. Despite this contraction, the ratio remains well above critical thresholds, indicating that the company maintains a strong capacity to meet its interest obligations, although the margin of safety has narrowed compared to 2022 levels.
Overall, the data reveals a company that has successfully lowered its overall debt burden and leverage. While the capacity to cover interest expenses has diminished from its 2022 peak, the strengthening of the balance sheet through reduced debt ratios suggests an improved long-term solvency position.
Debt Ratios
Coverage Ratios
Debt to Equity
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of solvency metrics from April 2022 through March 2026 reveals a general trend of deleveraging and a strengthening of the financial position. A consistent reduction in the debt-to-equity ratio suggests a strategic shift toward a more conservative capital structure over the observed period.
- Total Debt Trajectory
- Total debt exhibited a general downward trend, starting at 21,778 million USD in April 2022 and reaching a period low of 16,005 million USD by December 2024. A notable temporary spike occurred in September 2023, where debt increased to 22,060 million USD, before resuming a decline. The period concluded with total debt at 18,484 million USD in March 2026.
- Stockholders' Equity Performance
- Total stockholders' equity demonstrated a growth trend, rising from 46,356 million USD in April 2022 to a peak of 53,486 million USD in December 2023. Although subsequent quarters showed some volatility, including a dip to 49,543 million USD in December 2024, the equity base remained substantially higher than the initial 2022 levels, ending at 52,949 million USD in March 2026.
- Debt to Equity Ratio Interpretation
- The debt-to-equity ratio decreased from 0.47 in April 2022 to 0.35 in March 2026. The ratio reached its minimum value of 0.32 between December 2023 and December 2024. This contraction reflects a combined effect of reducing total debt and expanding the equity base, indicating an improved solvency profile and a reduced reliance on borrowed capital to fund operations and growth.
Debt to Capital
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the organization exhibits a general trend of deleveraging from early 2022 through early 2026. There is an observable reduction in the reliance on debt relative to the total capital structure, indicating a strengthened solvency position over the analyzed period.
- Total Debt Dynamics
- Total debt decreased from 21,778 million US$ in April 2022 to 18,484 million US$ by March 2026. While a temporary peak occurred in September 2023 at 22,060 million US$, the subsequent trend shows a consistent reduction, reaching a minimum of 16,005 million US$ in December 2024 before a slight increase in the final quarters.
- Total Capital Stability
- Total capital remained relatively stable throughout the observed period, fluctuating between a low of 65,548 million US$ in December 2024 and a peak of 74,467 million US$ in September 2023. The relative consistency of the capital base suggests that movements in the solvency ratio were primarily driven by active debt management rather than volatility in total capital.
- Debt to Capital Ratio Performance
- The debt to capital ratio declined from 0.32 in April 2022 to a floor of 0.24, which was maintained between December 2023 and December 2024. Following this period of minimum leverage, the ratio experienced a slight upward correction, settling at 0.26 by March 2026. The overall trajectory reflects a strategic reduction in financial leverage, lowering the organization's long-term solvency risk compared to the 2022 baseline.
Debt to Assets
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency analysis indicates a general improvement in the organization's capital structure over the observed period. The Debt to Assets ratio exhibits a consistent downward trajectory, transitioning from a peak of 0.26 in early 2022 to a stabilized range between 0.21 and 0.22 by early 2026, suggesting a reduction in the proportion of assets financed through debt.
- Debt to Assets Ratio Trends
- The ratio declined from 0.26 in April 2022 to 0.21 by December 2024. A temporary increase to 0.25 was observed in September 2023, which coincided with a peak in total debt. Following this spike, the ratio reached its lowest consistent level of 0.21 between December 2024 and September 2025, before marginally increasing to 0.22 in the final quarters of the period.
- Total Debt Dynamics
- Total debt levels experienced a general decline, starting at 21,778 million USD in April 2022 and reaching a minimum of 16,005 million USD in December 2024. Although debt increased again toward the end of the analyzed period, reaching 18,484 million USD by March 2026, the ending debt level remains substantially lower than the initial 2022 position.
- Asset Base Correlation
- Total assets remained relatively stable, fluctuating between a high of 87,734 million USD in September 2023 and a low of 77,542 million USD in December 2024. The improvement in the solvency ratio was primarily driven by the reduction in total debt rather than asset growth, as the ratio continued to decline even during periods where total assets were contracting.
Financial Leverage
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An analysis of the solvency metrics indicates a consistent reduction in financial leverage over the observed period, moving from a high of 1.80 in early 2022 to a stabilized range between 1.56 and 1.59 by the first quarter of 2026.
- Leverage Reduction Trend
- The financial leverage ratio experienced a steady decline from April 1, 2022, through December 31, 2023, dropping from 1.80 to 1.58. This trend reflects a shift toward a more conservative capital structure, as the growth in stockholders' equity consistently outpaced the expansion of total assets during this period.
- Asset and Equity Dynamics
- Total assets peaked at 87,734 million USD in September 2023 before contracting to a low of 77,542 million USD by December 2024. During the same timeframe, stockholders' equity increased from 46,356 million USD in April 2022 to a peak of 53,486 million USD in December 2023. The combination of rising equity and fluctuating asset levels contributed to the overall downward trajectory of the leverage ratio.
- Capital Structure Stabilization
- Beginning in March 2024, the financial leverage ratio entered a plateau phase, fluctuating minimally between 1.56 and 1.59. This stability persists through March 2026, suggesting that the organization has maintained a consistent proportion of debt relative to equity, effectively capping its financial risk profile at a lower level than that seen in 2022.
Interest Coverage
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||
| Less: Earnings from discontinued operations, net of income taxes | |||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Interest coverage
= (EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025)
÷ (Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Analysis of solvency ratios reveals a significant long-term contraction in interest coverage, moving from a peak of 41.32 in September 2022 to a stabilized range between 15.01 and 17.95 from early 2024 through March 2026.
- Operational Earnings Performance
- A clear downward trend in Earnings Before Interest and Tax (EBIT) is observed starting in early 2023. After peaking at 2,257 million USD in December 2022, EBIT declined sharply to 1,207 million USD by June 2023. Although the figures fluctuated between 1,064 million USD and 1,376 million USD throughout 2024, a secondary trough occurred in June 2025 at 726 million USD before recovering to 1,298 million USD by March 2026.
- Interest Expense Trends
- Interest expenses have remained relatively contained, fluctuating between a low of 42 million USD in September 2022 and a high of 87 million USD in September 2024. While there were periodic increases in cost, the volatility of interest expenses was significantly lower than the volatility observed in operational earnings.
- Interest Coverage Ratio Analysis
- The interest coverage ratio underwent a period of rapid erosion during 2023, falling from 35.60 in March to 18.64 by December. This decline is primarily attributable to the reduction in EBIT rather than a substantial increase in debt servicing costs. From March 2024 through March 2026, the ratio stabilized, oscillating within a narrow corridor between 15.01 and 17.95. Despite the reduction from 2022 levels, the ratio remains sufficiently high to indicate that operational earnings comfortably cover interest obligations.